CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-10 | Hampton Malcolm Garret Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2021-06-07 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +1,500 | $6.92 | $10K | 100,289 |
| 2021-06-07 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −1,500 | $20.22 | $30K | 98,789 |
| 2021-06-07 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −1,500 | 51,000 | ||
| 2021-05-28 | Stone Paul A. SVP, Chief Financial Officer | Grant or award | +859 | $11.36 | $10K | 13,803 |
| 2021-05-11 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +5,000 | $6.92 | $35K | 103,789 |
| 2021-05-11 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −5,000 | $20.22 | $101K | 98,789 |
| 2021-05-11 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −5,000 | 52,500 | ||
| 2021-02-24 | Dillon Michael P. SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2021-02-24 | Lackner Mark SVP, Head of Biology | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2021-02-24 | Throne Jason SVP, General Counsel | Grant or award · Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2021-02-24 | Hata Yujiro S President and CEO | Grant or award · Stock Option (right to buy) | +195,000 | 195,000 | ||
| 2021-02-24 | Stone Paul A. SVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2021-02-12 | Kelley Susan L. Director | Grant or award · Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2021-02-12 | Kelley Susan L. Director | Grant or award · Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2021-02-10 | Lackner Mark SVP, Head of Biology | Option exercise | +596 | $6.98 | $4K | 596 |
| 2021-02-10 | Lackner Mark SVP, Head of Biology | Sale | −596 | $21.00 | $13K | 0 |
| 2021-02-10 | Lackner Mark SVP, Head of Biology | Option exercise · Stock Option (right to buy) | −596 | 33,014 | ||
| 2021-02-09 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +5,000 | $6.92 | $35K | 103,789 |
| 2021-02-09 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −5,000 | $20.74 | $104K | 98,789 |
Page 12 of 19 · 370 trades